The mention of expanding the Mundipharma/ActiPatch relationship from the current 7 countries; Australia, New Zealand, Singapore, Malaysia, Thailand, Indonesia, Philippines, to a total of 20 was the best of the many positives released in the recent 'Shareholders Letter' for me.

No reinventing the wheel for this one. A billion dollar company that we are already doing business with wants to expand the relationship.

I was going to try an educated guess at the new countries from the knowledge that it would be a 13 country/territory expansion. However with Mundi having operations in 120 countries it was a bit overwhelming.

So the Great News is we should soon have 20 countries receiving ActiPatch through the Mundipharma Network and we still have 100 remaining for possible future expansion.

"Mundipharma Pharmaceuticals Limited is an Irish company and is part of a network of independent associated companies across Europe. This means that, while we can focus on the particular needs and demands of Irish healthcare, we have access to a pan-European knowledge and skills resource. We can ensure that the therapy areas we support can benefit from the newest ideas from Europe and from the rest of the world."

"The Mundipharma network of independent associated companies has a presence in more than 120 countries worldwide including over 30 in Europe."

"Mundipharma independent associated companies also have a presence in:
Russia, Greece and Turkey

Outside Europe: USA, Bermuda, Canada, China, Australia, New Zealand, Japan, South Korea and Singapore

Joint ventures in: Cyprus, India and Israel

Licensees in: Central and South America, Middle East, Africa and South East Asia"

http://www.mundipharma.ie/5-global-family

https://www.mundipharma.com/about-mundipharma...l-network/